Catalyst OrthoScience Announces First Surgeries Using Archer™ R1 Reverse Shoulder System

What Kind of Equipment is Used to Analyze DNA?

Below are some of a few basic processes followed throughout DNA testing. The general procedure entails:  • Isolating DNA from a sample containing the needed...

mJOULE Launches in the United Kingdom Reports Sciton

"Sciton is dedicated to worldwide support and growth. We continue to demonstrate our commitment to developing high quality devices and marketing efforts for our physician and medspa partners worldwide." says Lacee J. Naik, Vice President of Marketing and Public Relations.

FDA Issues Draft Guidance on Remanufacturing and Discussion Paper Seeking Feedback on Cybersecurity Servicing of Medical Devices

With this in mind, the FDA is issuing today's draft guidance to help clarify whether activities performed on medical devices are likely remanufacturing as well as a discussion paper on cybersecurity servicing of devices.

Catalyst OrthoScience Inc., a medical device company focused on the upper extremity orthopedics market, today announced the first surgeries using the new Archer™ R1 Reverse Shoulder System.

In March, the company received FDA 510(k) clearance and has kicked off a limited user release in Q2 2021. A commercial launch is planned for later in 2021. With the introduction of the Archer R1 system, Catalyst is addressing the two fastest-growing segments of the shoulder arthroplasty market – stemless anatomic and reverse TSA.

“Reverse shoulder arthroplasty encompasses more than 60 percent of the shoulder arthroplasty market,” said Brian K. Hutchison, chairman, and CEO of Catalyst. “These first surgeries with our Archer R1 reverse system went well, and we’re excited by the feedback we’re getting from the initial surgeon users.”

“We designed for the first time a single-tray reverse shoulder arthroplasty system which harnesses the best features of existing systems while maximizing ease-of-use, efficiency, and bone preservation, among other features,” said John G. Costouros, MD, chief of shoulder surgery at the Institute for Joint Restoration and Research, past professor Stanford University.  “My early experience has been exceptional.”

“These are very exciting times, working with the new Archer R1 system” said Zachary Leitze, MD, orthopedic surgeon at Intermountain Medical Group, St. George, Utah. “The system allowed for an efficient workflow through my surgeries. The humeral components perfectly centered in the metaphyseal cut, the glenoid prep was uncomplicated and the base plate secured well.”

“I am impressed with the workflow,” said Steven Goldberg, MD, orthopedic surgeon at Physicians Regional Medical Center, Naples, Fla. “The real bonus is not from what the system has, but what’s gone – the careful elimination of redundant steps or rarely used tools to make this incredibly efficient for the O.R. team.”

Catalyst’s Archer R1 reverse system is a single-tray arthroplasty system that was engineered to combine the most beneficial and evidence-based attributes of reverse shoulder arthroplasty design. The system offers surgeon-targeted implant positioning, a streamlined and versatile system, and bone sparing implants.

The system is a total shoulder prosthesis designed for patients experiencing severe shoulder arthritis in conjunction with a grossly deficient or non-functional rotator cuff. In a reverse shoulder system, the design is inverted compared to a traditional anatomic total shoulder prosthesis where the articulating sphere is on the glenoid side of the joint and the mating insert is fixed into the humeral stem implant.

Catalyst is one of the fastest-growing players in the anatomic stemless total shoulder arthroplasty market, starting with its popular Archer™ CSR Total Shoulder System. The Archer CSR system combines innovative components and unique instrumentation to bring about a precise, accurate restoration of the shoulder. It features a stemless, ellipsoid humeral component that is engineered to accurately replace the elliptical shape of the patient’s native non-spherical ​humeral head.

 

spot_img

DON'T MISS

Hyperfine Adds Medtech Leader and Visionary Scott Huennekens as Executive Chairman

Mr. Huennekens’ public boards include Chairman of Acutus Medical (IPO August 2020); Chairman of Envista (IPO September 2019); and board member of Nuvasive. He also serves as a board member and past Chairman of the Medical Device Manufacturer’s Association (MDMA).

One Drop Reports Carrie Siragusa, CPA Appointed VP of Commercial Strategy, Biosensor

Formerly Head of Innovation and Diabetes Portfolio at Sanofi, Siragusa will be part of a team bringing a multi-analyte dermal sensor (biosensor) with continuous health sensing capabilities to market with a mission to provide broader access to continuous glucose monitoring.

Barbara Moorhouse Appointed as Medica Non-Executive Director

Barbara has extensive business and management experience in the private, public, and regulated sectors.

Subscribe to Medical Device News Magazine here.

Related Articles